ArticleBeyoglu eye journal2025
Incidence of Retinopathy of Prematurity Between 2021 and 2024: Results from a Single Center.
Article in Beyoglu eye journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Retinopathy of prematurity (ROP) is a multifactorial disease characterized by abnormal vascularization of the immature retina. Although the most important risk factors are gestational age (GA) and birth weight (BW), the quality of neonatal intensive care also affects its incidence. This study aimed to evaluate the incidence of ROP and the need for treatment in infants screened for ROP according to the 2021 Turkish Prematurity Screening Guidelines for Retinopathy. Methods: Records of premature babies screened for ROP at a single center between January 2021 and December 2024 were retrospectively evaluated. The results of the examinations, need for treatment, and hospital centers where premature infants were examined in accordance with the new guidelines were recorded. Results: Between 2021 and 2024, 8,503 premature infants were screened for ROP at our clinic. A total of 1,623 infants were diagnosed with ROP, and 147 were treated using either laser photocoagulation or intravitreal bevacizumab. The number of babies with a BW over 1,700 g who were screened for ROP was 6,581; of these, 738 (11.21%) developed ROP, and 28 babies (0.42%) were treated. The number of babies born at ≥34 weeks' GA and who were screened for ROP was 4,029; of these, 173 (4.29%) developed ROP, and one baby (0.024%) was treated. Among the 1,623 patients diagnosed with ROP, 147 were treated, and 1,476 had spontaneously regressed ROP. Conclusion: Significant ROP requiring treatment may occur in infants born at >34 weeks of gestation and/or with a BW ≥1,700 g.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.